YPEG-rhG-CSF

pegylated recombinant human granulocyte colony-stimulating factor · Xiamen Amoytop Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for YPEG-rhG-CSF, covering 2018-07-17 to 2022-02-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy [Phase 3]

See pricing